---
layout: default
title: Anastrozole
description: "Anastrozole çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æœ€é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 23
evidence_level: L1
indication_count: 6
---

# Anastrozole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Anastrozoleï¼šå¾åœç¶“å¾Œä¹³ç™Œåˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Anastrozole å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Anastrozole åŸæœ¬ç”¨æ–¼æ²»ç™‚åœç¶“å¾Œå©¦å¥³æ™šæœŸä¹³ç™ŒåŠè¼”åŠ©æ²»ç™‚æ—©æœŸä¹³ç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **50+ å€‹è‡¨åºŠè©¦é©—**å’Œ **20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åœç¶“å¾Œå©¦å¥³æ™šæœŸä¹³ç™Œã€è·çˆ¾è’™æ¥å—å™¨é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©æ²»ç™‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€ç¥ç¶“æ¯ç´°èƒç˜¤ã€vertebral anomalies and variable endocrine and T-cell dysfunctionã€ganglioneuroblastoma (disease)ã€è…¹è†œå¾Œè…«ç˜¤ã€å–®æ ¸ç´°èƒç™½è¡€ç—… |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.68% |
| è­‰æ“šç­‰ç´š | L1 |
| å°ç£ä¸Šå¸‚ | æœ‰ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 20 å¼µ |
| å»ºè­°æ±ºç­– | Already Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§) |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.68%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Anastrozole æ˜¯ç¬¬ä¸‰ä»£éé¡å›ºé†‡èŠ³é¦™ç’°é…¶æŠ‘åˆ¶åŠ‘ï¼Œå…¶ä½œç”¨æ©Ÿè½‰ï¼š</p>

<ol>
<li><strong>æŠ‘åˆ¶èŠ³é¦™ç’°é…¶</strong>ï¼šé¸æ“‡æ€§æŠ‘åˆ¶èŠ³é¦™ç’°é…¶ï¼ˆCYP19ï¼‰ï¼Œé˜»æ–·é›„æ¿€ç´ è½‰åŒ–ç‚ºé›Œæ¿€ç´ </li>
<li><strong>é™ä½é›Œæ¿€ç´ æ¿ƒåº¦</strong>ï¼šå¯å°‡åœç¶“å¾Œå©¦å¥³è¡€æ¸…é›Œæ¿€ç´ æ¿ƒåº¦é™ä½ç´„80-90%</li>
<li><strong>æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·</strong>ï¼šå°é›Œæ¿€ç´ å—é«”é™½æ€§ä¹³ç™Œï¼Œæ¸›å°‘é›Œæ¿€ç´ åˆºæ¿€å¯æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·</li>

</ol>
<p>é æ¸¬é©æ‡‰ç—‡ã€Œå¥³æ€§ä¹³è…ºç™Œã€èˆ‡åŸé©æ‡‰ç—‡é«˜åº¦é‡ç–Šï¼Œæ­¤é æ¸¬å°è­‰äº†æ¨¡å‹å° anastrozole åœ¨ä¹³ç™Œæ²»ç™‚ä¸­è§’è‰²çš„æ­£ç¢ºè­˜åˆ¥ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05700006" target="_blank">NCT05700006</a></td><td>N/A</td><td>ACTIVE_NOT_RECRUITING</td><td>100</td><td>An Observational Study of Women With Breast Cancer Examining the Effect of Endoc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02206984" target="_blank">NCT02206984</a></td><td>PHASE2</td><td>COMPLETED</td><td>201</td><td>A Trial of Endocrine Response in Women With Invasive Lobular Breast Cancer</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00323479" target="_blank">NCT00323479</a></td><td>PHASE4</td><td>COMPLETED</td><td>114</td><td>A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEXÂ® (1mg/Day) as...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02730091" target="_blank">NCT02730091</a></td><td>PHASE3</td><td>TERMINATED</td><td>98</td><td>A Randomized Open Study of Metronomic Oral Vinorelbine in Combination With Aroma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02188550" target="_blank">NCT02188550</a></td><td>PHASE2</td><td>UNKNOWN</td><td>20</td><td>Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatm...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00255463" target="_blank">NCT00255463</a></td><td>PHASE2</td><td>COMPLETED</td><td>185</td><td>Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicen...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03081234" target="_blank">NCT03081234</a></td><td>PHASE3</td><td>WITHDRAWN</td><td>0</td><td>A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02476786" target="_blank">NCT02476786</a></td><td>PHASE2</td><td>RECRUITING</td><td>50</td><td>Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estroge...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00573755" target="_blank">NCT00573755</a></td><td>PHASE2</td><td>TERMINATED</td><td>4</td><td>Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04272801" target="_blank">NCT04272801</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>84</td><td>Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy D...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00287534" target="_blank">NCT00287534</a></td><td>PHASE2</td><td>COMPLETED</td><td>1059</td><td>A Prospective, Multi-Centre, Randomised, Open Parallel Group Study to Compare th...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03822468" target="_blank">NCT03822468</a></td><td>PHASE2</td><td>COMPLETED</td><td>376</td><td>A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00555477" target="_blank">NCT00555477</a></td><td>PHASE2</td><td>TERMINATED</td><td>69</td><td>Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00784862" target="_blank">NCT00784862</a></td><td>PHASE3</td><td>COMPLETED</td><td>9358</td><td>A Randomised, Double Blind Trial to Assess the Pharmacokinetics of Arimidex Alon...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02095184" target="_blank">NCT02095184</a></td><td>NA</td><td>COMPLETED</td><td>42</td><td>GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01216176" target="_blank">NCT01216176</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>71</td><td>A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01896050" target="_blank">NCT01896050</a></td><td>N/A</td><td>COMPLETED</td><td>115</td><td>A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Canc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02823262" target="_blank">NCT02823262</a></td><td>NA</td><td>TERMINATED</td><td>65</td><td>A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00186121" target="_blank">NCT00186121</a></td><td>PHASE2</td><td>COMPLETED</td><td>35</td><td>A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00555867" target="_blank">NCT00555867</a></td><td>N/A</td><td>TERMINATED</td><td>4923</td><td>A Randomised in Practice Evaluation of the Influence of Patient&#x27;s Understanding ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01402193" target="_blank">NCT01402193</a></td><td>PHASE3</td><td>UNKNOWN</td><td>220</td><td>A Prospective, Randomized, Bi-center Study to Compare the Outcome of Adjuvant Ra...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06507618" target="_blank">NCT06507618</a></td><td>PHASE3</td><td>RECRUITING</td><td>354</td><td>A Randomized, Phase III Trial of Pre-Operative Window of Endocrine Therapy to In...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06016738" target="_blank">NCT06016738</a></td><td>PHASE3</td><td>RECRUITING</td><td>510</td><td>A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Car...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01783444" target="_blank">NCT01783444</a></td><td>PHASE2</td><td>COMPLETED</td><td>309</td><td>A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00562458" target="_blank">NCT00562458</a></td><td>N/A</td><td>COMPLETED</td><td>200</td><td>ARIMIDEX Study ( Non-interventional Study to Evaluate Arimidex in Adjuvant Thera...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00543127" target="_blank">NCT00543127</a></td><td>PHASE3</td><td>TERMINATED</td><td>870</td><td>Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05501704" target="_blank">NCT05501704</a></td><td>PHASE2</td><td>RECRUITING</td><td>60</td><td>ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06492616" target="_blank">NCT06492616</a></td><td>PHASE3</td><td>RECRUITING</td><td>4220</td><td>Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positiv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03778931" target="_blank">NCT03778931</a></td><td>PHASE3</td><td>COMPLETED</td><td>478</td><td>Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00111241" target="_blank">NCT00111241</a></td><td>N/A</td><td>COMPLETED</td><td>115</td><td>Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04088110" target="_blank">NCT04088110</a></td><td>PHASE2</td><td>UNKNOWN</td><td>77</td><td>Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the Firs...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00641303" target="_blank">NCT00641303</a></td><td>NA</td><td>COMPLETED</td><td>51</td><td>A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04236310" target="_blank">NCT04236310</a></td><td>PHASE2</td><td>UNKNOWN</td><td>37</td><td>A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and T...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07071038" target="_blank">NCT07071038</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>62</td><td>The &#x27;SWIVEL&#x27; Study (Switch Vs Effects Relief): Effectiveness of a Medication &#x27;Sw...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00508586" target="_blank">NCT00508586</a></td><td>PHASE1</td><td>COMPLETED</td><td>33</td><td>A Phase 1b Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00784680" target="_blank">NCT00784680</a></td><td>PHASE3</td><td>COMPLETED</td><td>308</td><td>A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00661531" target="_blank">NCT00661531</a></td><td>PHASE2</td><td>TERMINATED</td><td>11</td><td>A Single Arm Phase II Study of Pharmacologic Dose Estrogen in Postmenopausal Wom...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00537771" target="_blank">NCT00537771</a></td><td>PHASE4</td><td>COMPLETED</td><td>384</td><td>A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04852081" target="_blank">NCT04852081</a></td><td>N/A</td><td>UNKNOWN</td><td>1000</td><td>Analysis of Therapy Sequence in Women With Hormone Receptor-positive, HER2-negat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03272477" target="_blank">NCT03272477</a></td><td>PHASE2</td><td>COMPLETED</td><td>257</td><td>A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Co...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00762294" target="_blank">NCT00762294</a></td><td>N/A</td><td>COMPLETED</td><td>25</td><td>Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral De...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01016665" target="_blank">NCT01016665</a></td><td>NA</td><td>COMPLETED</td><td>71</td><td>Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Ter...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04767594" target="_blank">NCT04767594</a></td><td>N/A</td><td>ACTIVE_NOT_RECRUITING</td><td>1409</td><td>PERFORM: An EPidEmiological, PRospective Cohort Study to Generate Real-world Evi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03078751" target="_blank">NCT03078751</a></td><td>PHASE2</td><td>COMPLETED</td><td>54</td><td>An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00570323" target="_blank">NCT00570323</a></td><td>PHASE2</td><td>COMPLETED</td><td>72</td><td>A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopau...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05837455" target="_blank">NCT05837455</a></td><td>PHASE2</td><td>RECRUITING</td><td>81</td><td>NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy f...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00398489" target="_blank">NCT00398489</a></td><td>PHASE2</td><td>UNKNOWN</td><td>94</td><td>Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00405938" target="_blank">NCT00405938</a></td><td>PHASE2</td><td>COMPLETED</td><td>79</td><td>A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02441946" target="_blank">NCT02441946</a></td><td>PHASE2</td><td>COMPLETED</td><td>224</td><td>neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 We...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00143390" target="_blank">NCT00143390</a></td><td>PHASE3</td><td>COMPLETED</td><td>298</td><td>A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) Vs Anastro...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31839281/" target="_blank">31839281</a></td><td>2020</td><td>Article</td><td>Lancet (London, England)</td><td>Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15639680/" target="_blank">15639680</a></td><td>2005</td><td>Article</td><td>Lancet (London, England)</td><td>Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20923259/" target="_blank">20923259</a></td><td>2010</td><td>Article</td><td>Expert opinion on drug safety</td><td>Anastrozole.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14687437/" target="_blank">14687437</a></td><td>2003</td><td>Article</td><td>Current medical research and o</td><td>Focus on anastrozole and breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28614542/" target="_blank">28614542</a></td><td>2017</td><td>Article</td><td>Revista da Associacao Medica B</td><td>Use of anastrozole in the chemoprevention and treatment of breast cancer: A lite...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16034487/" target="_blank">16034487</a></td><td>2005</td><td>Article</td><td>Drugs of today (Barcelona, Spa</td><td>Anastrozole.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26160683/" target="_blank">26160683</a></td><td>2015</td><td>Article</td><td>Maturitas</td><td>Testosterone and breast cancer prevention.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30499075/" target="_blank">30499075</a></td><td>2020</td><td>Article</td><td>Pathology oncology research : </td><td>Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24912489/" target="_blank">24912489</a></td><td>2014</td><td>Article</td><td>Oncotarget</td><td>Anastrozole and everolimus in advanced gynecologic and breast malignancies: acti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16761927/" target="_blank">16761927</a></td><td>2006</td><td>Article</td><td>Expert review of anticancer th</td><td>Anastrozole for breast cancer: recent advances and ongoing challenges.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34048027/" target="_blank">34048027</a></td><td>2021</td><td>Article</td><td>Clinical pharmacology and ther</td><td>Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in E...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32701512/" target="_blank">32701512</a></td><td>2020</td><td>Article</td><td>JCI insight</td><td>Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and add...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16439860/" target="_blank">16439860</a></td><td>2006</td><td>Article</td><td>Oncology</td><td>Role of anastrozole across the breast cancer continuum: from advanced to early d...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19445563/" target="_blank">19445563</a></td><td>2009</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Comparative review of anastrozole, letrozole and exemestane in the management of...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12113022/" target="_blank">12113022</a></td><td>2001</td><td>Article</td><td>Expert review of anticancer th</td><td>Anastrozole: pharmacological and clinical profile in postmenopausal women with b...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39275052/" target="_blank">39275052</a></td><td>2024</td><td>Article</td><td>Molecules (Basel, Switzerland)</td><td>Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17033446/" target="_blank">17033446</a></td><td>2006</td><td>Article</td><td>European journal of gastroente</td><td>Anastrozole-induced hepatotoxicity.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21885816/" target="_blank">21885816</a></td><td>2011</td><td>Article</td><td>Cancer prevention research (Ph</td><td>Changes in breast density and circulating estrogens in postmenopausal women rece...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26686313/" target="_blank">26686313</a></td><td>2016</td><td>Article</td><td>Lancet (London, England)</td><td>Anastrozole versus tamoxifen for the prevention of locoregional and contralatera...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32632513/" target="_blank">32632513</a></td><td>2020</td><td>Article</td><td>Breast cancer research and tre</td><td>Genetic and clinical predictors of arthralgia during letrozole or anastrozole th...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. vertebral anomalies and variable endocrine and T-cell dysfunction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. ganglioneuroblastoma (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.41%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. retroperitoneal neoplasm</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.33%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21403449/" target="_blank">21403449</a></td><td>2011</td><td>Article</td><td>Gan to kagaku ryoho. Cancer &amp; </td><td>[A case of possible retroperitoneal metastasis of breast cancer successfully tre...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. monocytic leukemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.16%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|---------|------|------|-------------|------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬022282è™Ÿ | å®‰ç¾é”éŒ 1æ¯«å…‹ | è†œè¡£éŒ  | è‡ºç£é˜¿æ–¯ç‰¹æ·åˆ©åº· | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬047539è™Ÿ | å®‰ç´æŸ”è†œè¡£éŒ  | è†œè¡£éŒ  | å°ç£æ±æ´‹è—¥å“ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬055555è™Ÿ | åŸ¹åŠ›å®‰è«¾å¦¥è†œè¡£éŒ  | è†œè¡£éŒ  | åŸ¹åŠ›è—¥å“ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬056730è™Ÿ | æè¼å®‰å¨œæ–¯æŸ”è†œè¡£éŒ  | è†œè¡£éŒ  | æè¼è—¥å“ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026515è™Ÿ | å®‰ç‘ç‰¹è†œè¡£éŒ  | è†œè¡£éŒ  | å‡±æ²›çˆ¾è—¥å“ | æœ‰æ•ˆ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | éç´°èƒæ¯’æ€§ï¼ˆè·çˆ¾è’™ç™‚æ³•ï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | æ¥µä½ |
| è‡´åæ€§åˆ†ç´š | æ¥µä½ |
| ç›£æ¸¬é …ç›® | éª¨å¯†åº¦ã€è¡€è„‚ã€è‚åŠŸèƒ½ |
| è™•ç½®é˜²è­· | ä¸€èˆ¬è—¥ç‰©è™•ç½®å³å¯ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - èˆ‡ Tamoxifen ä½µç”¨æœƒé™ä½ anastrozole è¡€ä¸­æ¿ƒåº¦ï¼Œä¸å»ºè­°åˆä½µä½¿ç”¨
  - èˆ‡å«é›Œæ¿€ç´ è£½åŠ‘ä½µç”¨æœƒé™ä½ç™‚æ•ˆ
- **ä¸»è¦å‰¯ä½œç”¨**ï¼š
  - éª¨è³ªç–é¬†ã€éª¨æŠ˜é¢¨éšªå¢åŠ 
  - é—œç¯€ç—›ã€è‚Œè‚‰ç—›ï¼ˆç´„50%æ‚£è€…ï¼‰
  - æ½®ç´…ã€ç›œæ±—
  - è¡€è„‚ç•°å¸¸
- **ç¦å¿Œç—‡**ï¼š
  - åœç¶“å‰å©¦å¥³
  - æ‡·å­•åŠå“ºä¹³æœŸ
  - åš´é‡è‚åŠŸèƒ½ä¸å…¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šè‘¡è„æŸšå° Anastrozole å½±éŸ¿è¼ƒå°
- å»ºè­°ï¼šç„¡éœ€ç‰¹åˆ¥é™åˆ¶


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**å¿ƒè¡€ç®¡ç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Hypercholesterolemia** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**éª¨è³ªç–é¬†ç—‡** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šAlready Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§)**

**ç†ç”±ï¼š**
é æ¸¬é©æ‡‰ç—‡ã€Œå¥³æ€§ä¹³è…ºç™Œã€å¯¦éš›ä¸Šæ˜¯åŸæ ¸å‡†é©æ‡‰ç—‡çš„ä¸€èˆ¬æ€§æè¿°ã€‚Anastrozole å·²æ˜¯åœç¶“å¾Œè·çˆ¾è’™å—é«”é™½æ€§ä¹³ç™Œçš„æ¨™æº–æ²»ç™‚è—¥ç‰©ä¹‹ä¸€ã€‚å¤§é‡è‡¨åºŠè©¦é©—ï¼ˆå¦‚ ATACã€IBIS-IIï¼‰å·²è­‰å¯¦å…¶ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ã€‚

**è‡¨åºŠå»ºè­°ï¼š**
- é™ç”¨æ–¼åœç¶“å¾Œå©¦å¥³æˆ–åµå·¢åŠŸèƒ½æŠ‘åˆ¶å¾Œçš„å©¦å¥³
- å®šæœŸç›£æ¸¬éª¨å¯†åº¦ï¼Œå¿…è¦æ™‚çµ¦äºˆéª¨è³ªä¿è­·åŠ‘
- æ³¨æ„é—œç¯€ç—‡ç‹€çš„è™•ç†ï¼Œä»¥æå‡æ²»ç™‚é †å¾æ€§
- èˆ‡ CDK4/6 æŠ‘åˆ¶åŠ‘ä½µç”¨å¯é€²ä¸€æ­¥æå‡æ™šæœŸä¹³ç™Œç™‚æ•ˆ

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Docetaxel]({{ "/drugs/docetaxel/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - è­‰æ“šç­‰ç´š L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Anastrozoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/anastrozole/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_anastrozole,
  title = {Anastrozoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/anastrozole/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
